Reunion Neuroscience Inc. Announces 2022 Annual General Meeting of Shareholders
31 Agosto 2022 - 6:30AM
Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) ("Reunion"), or
(“the Company”), a global leader in the discovery and development
of innovative of psychedelic-inspired therapeutics for improved
mental health outcomes, today announced it has scheduled its 2022
Annual General Meeting of Shareholders for September 29, 2022 at
10:00 AM ET.
Shareholders of record on August 23, 2022 will
be able to vote and ask questions online during the meeting. The
Meeting will be available virtually and all Shareholders are urged
to listen to the Meeting as follows.
To join the Meeting virtually, please join via
the following link:
https://app.livestorm.co/field-trip-health-1/reunion-neuroscience-annual-general-meeting?type=detailed
for registration and follow the online instructions. After
registering, you will receive a confirmation email with information
about joining the Meeting virtually. Questions can be asked by
typing in the question in the virtual platform at any time during
the Meeting.
To join the Meeting via teleconference, please
register via the following link:
https://app.livestorm.co/field-trip-health-1/reunion-neuroscience-annual-general-meeting?type=detailed
and follow the online instructions. You will then access the
webinar on the day of to receive a personalized dial-in number and
code. Note that those dialing-in will be in “listen only” mode.
For further instructions on how to dial in,
please visit the following page: https://support.livestorm.co/
article/110-dial-in.
Please note that you will not be able to vote
virtually. If you intend to listen to the Meeting virtually you
must vote on the matters prior to the Meeting. Votes must be
received by Computershare no later than the Proxy Deadline.
Shareholders of record as of August 23, 2022
will be eligible to vote and participate in the Annual Meeting.
Reunion’s 2022 Notice of Meeting, Management Information Circular
and 2022 Annual Report on Form 10-K are available on its SEDAR and
EDGAR profiles available at www.sedar.com or
https://www.sec.gov/edgar. The Notice of Meeting and Management
Information Circular contain further information on voting and
admission procedures.
About Reunion Neuroscience Inc.,
(formerly, Field Trip Health Ltd.)
Reunion is a leader in novel psychedelic drug
development, committed to innovating therapeutic solutions for
mental health conditions by developing proprietary serotonin
receptor agonist compounds. The Company’s lead asset, RE-104
(previously known as FT-104), is a proprietary, novel psychedelic
drug being developed for post-partum and treatment resistant
depression as a potential fast-acting antidepressant with durable
efficacy. Reunion is also developing the FT-200 series, which
includes compounds with potential for more selective serotonin
receptor activity with reduced psychoactivity for potential use in
more chronic treatment paradigms and indications.
Learn more at https://investors.reunionneuro.com, and
https://www.reunionneuro.com.
Follow us on Twitter and Instagram:
@reunionneuro.
To be added to the Reunion Neuroscience email
list, please email Reunion@kcsa.com with “REUN” in the subject
line.
Cautionary Note Regarding
Forward-Looking Information
This release includes forward-looking
information (within the meaning of Canadian securities laws and
within the meaning of the United States Private Securities
Litigation Reform Act of 1995) regarding the Company and its
business. Often but not always, forward-looking information can be
identified by the use of words such as "expect", "intends",
"anticipated", "believes" or variations (including negative
variations) of such words and phrases, or state that certain
actions, events or results "may", "could", "would" or "will" be
taken, occur or be achieved. Such statements are based on the
current expectations and views of future events of the management
of the Company and are based on assumptions and subject to risks
and uncertainties. Although the management of believes that the
assumptions underlying these statements are reasonable, they may
prove to be incorrect. The forward-looking events and circumstances
discussed in this release may not occur and could differ materially
as a result of known and unknown risk factors and uncertainties
affecting the companies. Although the Company has attempted to
identify important factors that could cause actual actions, events
or results to differ materially from those described in
forward-looking statements, there may be other factors that cause
actions, events or results to differ from those anticipated,
estimated or intended. Accordingly, readers should not place undue
reliance on any forward-looking statements or information. No
forward-looking statement can be guaranteed. Except as required by
applicable securities laws, forward-looking statements speak only
as of the date on which they are made and the Company does not
undertake any obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future events, or otherwise. Additional information relating to
Field Trip, including its Annual Information Form, can be located
on the SEDAR website at www.sedar.com and on the EDGAR section of
the SEC’s website at www.sec.gov.
Neither Toronto Stock Exchange, or its
Regulation Services Provider, have approved the contents of this
release or accept responsibility for the adequacy or accuracy of
this release.
CONTACTS:
Reunion Neuroscience:Joseph del MoralChairman
& CEO(416) 219-1050joseph@reunionneuro.com
Media contacts:Caitlin KasunichKCSA Strategic
Communications(212) 896-1241reunion@kcsa.com
Investor contacts:Phil Carlson / Sophia
BashfordKCSA Strategic Communications(646) 573-0776 / (929)
246-7307reunion@kcsa.com
SOURCE Reunion Neuroscience Inc.
Reunion Neuroscience (TSX:REUN)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Reunion Neuroscience (TSX:REUN)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024